1. 181P SELECT: A phase II randomized trial evaluating 2 doses of vopratelimab (V) + pimivalimab (P) vs P in TISvopra selected patients (pts). (December 2022) Authors: Gumus, M.; Sukalinskaya, A.; Andric, Z.G.; Cheshuk, V.; Ciuleanu, T-E.; Sezgin Goksu, S.; Cil, T.; Cicin, I.; Bulat, I.V.; Ostapenko, Y.V.; Penkov, K.D.; Hart, C.; Lai, M.; Chaao, B.; Jimenez, J.; Sepahi, A.; Shi, G.; Trott, S.; Hooper, E. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗